Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDOCYP2D6: Metabolomics for CYP2D6 Biomarkers
NCT04188028Completed
- Start
- Jan 2019
- Primary completion
- Jul 2019
- Countries
- 1
01
Overview
Open-label trial (2 arms). Primary endpoint: Identify endogenous markers of CYP2D6 activity in urine and plasma using untargeted metabolomics at 7 days. Started Jan 2019; status: completed.
Beyond the preview
Go deeper on NCT04188028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188028.